Serum leptin, adiponectin, and resistin among adult patients with acanthosis nigricans: Correlations with insulin resistance and risk factors for cardiovascular disease

International Journal of Dermatology

Volumn 53, Issue 10, 2014, Pages e410-e420

  Atwa, Mona ^a   Emara, Amany ^b   Balata, Mona ^b   Youssef, Nahed ^a   Bayoumy, Nervana ^c   Sherif, Abdulsalam ^d   Fiala, Lamia ^a  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; RESISTIN; TRIACYLGLYCEROL;

ACANTHOSIS NIGRICANS; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLIC SYNDROME X; METABOLISM; RISK FACTOR;

ACANTHOSIS NIGRICANS; ADIPONECTIN; ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; METABOLIC SYNDROME X; RESISTIN; RISK FACTORS;

EID: 84907810379     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12340     Document Type: Article

References (45)

1. Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 2007; 56: 901-916.
2. Maitra SK, Payne CMER. The obesity syndrome and acanthosis nigricans. Acanthosis nigricans is a common cosmetic problem providing epidemiological clues to the obesity syndrome, the insulin-resistance syndrome, the thrifty metabolism, dyslipidemia, hypertension and diabetes mellitus type II. J Cosmet Dermatol 2004; 3: 202-210.
3. Stuart CA, Smith MM, Gilkison CR, et al. Acanthosis nigricans among Native Americans: an indicator of high diabetes risk. Am J Public Health 1994; 84: 1839-1842.
4. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420-426.
5. Moller DE, Flier JS. Insulin resistance - mechanisms, syndromes, and implications. New Engl J Med 1991; 325: 938-948.
6. Cruz PD Jr, Hud JA Jr. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Investig Dermatol 1992; 98(6 Suppl.): 82-85.
7. Suzuki M, Odaka H. Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat. Nippon Rinsho 2003; 61: 1119-1123.
8. Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
9. Laakso M. Insulin resistance and coronary heart disease. Curr Opin Lipidol 1996; 7: 217-226.
10. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996; 124: 110-116.
11. Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and White children. J Pediatr 2001; 138: 474-480.
12. Kobaissi HA, Weigensberg MJ, Ball GDC, et al. Relation between acanthosis nigricans and insulin sensitivity in overweight Hispanic children at risk for type 2 diabetes. Diabetes Care 2004; 27: 1412-1416.
13. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol 2006; 57: 505-528.
14. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin - the classical, resistin - the controversial, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-546.
15. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879-884.
16. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30: 13-19.
17. Ciccone M, Vettor R, Pannacciulli N, et al. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25: 805-810.
18. Wolk R, Berger P, Lennon RJ, et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44: 1819-1824.
19. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056.
20. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
21. Okamoto Y, Kihara S, Funahashi T, et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267-278.
22. Iwashima Y, Katsuya T, Ishikawa K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
23. McTernan CL, McTernan PG, Harte AL, et al. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-47.
24. Mora-Janiszewska O, Kulik-Rechberger B, Rechberger T. The role of insulin resistance and resistin in pathogenesis of diabetes mellitus with special attention to diabetes in pregnancy. Ginekol Pol 2005; 76: 580-585.
25. Anderlova K, Kremen J, Dolezalova R, et al. The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. Physiol Res 2006; 55: 277-283.
26. Reilly MP, Lehrke M, Wolfe ML, et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939.
27. Chu S, Ding W, Li K, et al. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008; 72: 1249-1253.
28. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment. Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
29. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
30. McAuley KA, Williams SM, Mann JI, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-464.
31. Lin TC, Yen JM, Gong KP, et al. Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population - not correlated with insulin receptor substrate-1 Gly972Arg/ Ala513Pro polymorphism. BMC Med Genet 2006; 7: 1-8.
32. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, et al. Obesity in Saudi Arabia. Saudi Med J 2005; 26: 824-829.
33. Mei Z, Scanlon KS, Grummer-Strawn LM, et al. Increasing prevalence of overweight among US low-income preschool children: the Centers for Disease Control and Prevention pediatric nutrition surveillance, 1983 to 1995. Pediatrics 1998; 101: 112.
34. Heini AF, Weinsier RL. Divergent trends in obesity and fat intake patterns: the American paradox. Am J Med 1997; 102: 259-264.
35. Hud JA Jr, Cohen JB, Wagner JM, et al. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992; 128: 941-944.
36. Hirschler V, Aranda C, Oneto A, et al. Is acanthosis nigricans a marker of insulin resistance in obese children? Diabetes Care 2002; 25: 2353.
37. Yamazaki H, Ito S, Yoshida H. Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children. Pediatr Int 2003; 45: 701- 705.
38. Miura N, Ikezaki A, Iwama S, et al. Genetic factors and clinical significance of acanthosis nigricans in obese Japanese children and adolescents. Acta Paediatr 2006; 95: 170-175.
39. Guran T, Turan S, Akcay T, et al. Significance of acanthosis nigricans in childhood obesity. J Paediatr Child Health 2008; 44: 338-341.
40. Litonjua P, Pinero-Pilona A, Aviles-Santa L, et al. Prevalence of acanthosis nigricans in newly diagnosed type 2 diabetes. Endocr Pract 2004; 10: 101-106.
41. Mukhtar Q, Cleverley G, Voorhees RE, et al. Prevalence of acanthosis nigricans and its association with hyperinsulinemia in New Mexico adolescents. J Adolesc Health 2001; 28: 372-376.
42. Stoddart ML, Blevins KS, Lee ET, et al. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care 2002; 25: 1009-1014.
43. Copeland K, Pankratz K, Cathey V, et al. Acanthosis nigricans, insulin resistance (HOMA) and dyslipidemia among Native American children. J Okla State Med Assoc 2006; 99: 19-24.
44. Kong AS, Williams RL, Smith M, et al. Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in southwestern US primary care practices. Ann Fam Med 2007; 5: 202-208.
45. Bonet B, Viana M, Sánchez-Verat I, et al. Adipose tissue and liver lipid metabolism in obese children: role of the body mass index and the presence of acanthosis nigricans. Diabet Med 2007; 24: 1192-1198.